Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

Inclusion Criteria: * Patients of any age with diagnosis of: * Relapsed/refractory lymphoma (B cell non-Hodgkin) who have lack of objective response to at least two prior chemotherapy regimens * Relapsed chronic lymphocytic leukemia with high risk features: lack of objective response or relapse within 6 months following nucleoside-analogue based chemotherapy regimen or patients with 17p deletion CLL who lacked objective response to at least 1 preceding chemotherapy regimen * Available related HLA haploidentical NK cell donor by at least Class I serologic typing at the A\&B locus (age 12-75 years) * Karnofsky \> 70% for patients 16 years and older and Lansky play score \> 50 for patients under 16 years of age * Measurable disease based on modified Response Evaluation Criteria in Solid Tumors (RECIST) * Have acceptable organ function as defined within 28 days of enrollment: * Hematologic: platelets ≥ 80,000 x 10\^9/L; hemoglobin ≥ 9 g/dL, unsupported by transfusions within 7 days; absolute neutrophile count (ANC) ≥ 1000 x 10\^9/L, unsupported by Granulocyte colony-stimulating factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) for 10 days or Neulasta for 21 days - the hematologic requirements are waived for patients with inadequate counts due to known bone marrow involvement by disease who are otherwise eligible * Renal: calculated glomerular filtration rate (GFR) \> 50 ml/min * Hepatic: Alanine aminotransferase (ALT) and aspartate aminotran…